Back to Newsroom

Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine

GAITHERSBURG, Md., February 28, 2018 — Novavax, Inc., (Nasdaq:NVAX) today announced positive top-line results from its Phase 1/2 clinical trial in older adults of its NanoFlu recombinant influenza vaccine, which includes its proprietary Matrix-M™ adjuvant, compared to the leading licensed egg-based, high-dose influenza vaccine for older adults (IIV3-HD).